{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:48:11Z","timestamp":1790419691688,"version":"4.1.0"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T00:00:00Z","timestamp":1731369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>The clinical significance of elevated baseline serum tryptase (BST) in the absence of mast cell disorders or allergic reactions has long been unclear. Recently, a genetic variation of the <jats:italic>TPSAB1<\/jats:italic> gene, which among others encodes for alpha tryptase, has been reported and named hereditary alpha tryptasemia (HaT). HaT has been linked to various manifestations, including severe allergic reactions. However, clinical studies are limited. In this study, we aimed to determine HaT prevalence and characterize its clinical manifestations in patients at a specialized allergy center.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>From January 2022 to December 2023, patients with elevated BST at least once were screened for HaT at the outpatient clinic. A control group included patients with a history of anaphylaxis undergoing specific Hymenoptera immunotherapy. <jats:italic>TPSAB1<\/jats:italic> copy numbers, BST levels, and clinical parameters were assessed and analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 47 patients with elevated BST (\u226511.4\u2005\u00b5g\/L), 93% showed increased <jats:italic>TPSAB1<\/jats:italic> copy numbers. Individuals diagnosed with HaT displayed a BST range between 12.3 and 28.4\u2005\u00b5g\/L, with 84.1% associated with <jats:italic>TPSAB1<\/jats:italic> duplication and 15.9% with triplication. HaT predominated in women (86.4%) and was associated with thyroid disease (27.3%). Over half had a history of anaphylaxis (54.5%), which was mainly low-grade.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>In patients with elevated BST but no mastocytosis, the most likely cause of elevated BST was an increase in the copy number of the <jats:italic>TPSAB1<\/jats:italic> gene. A heightened risk of anaphylaxis should be considered. Further research is needed to explore the predominance of women and the emerging link with thyroid disease.<\/jats:p><\/jats:sec>","DOI":"10.3389\/falgy.2024.1461359","type":"journal-article","created":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T06:16:33Z","timestamp":1731392193000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Hereditary alpha tryptasemia: elevated tryptase, female sex, thyroid disorders, and anaphylaxis"],"prefix":"10.3389","volume":"5","author":[{"given":"Viktoria","family":"Puxkandl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Aigner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfram","family":"Hoetzenecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Altrichter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1182\/blood-2016-09-731893","article-title":"Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts","volume":"129","author":"Valent","year":"2017","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","article-title":"Diagnostic criteria and classification of mastocytosis: a consensus proposal","volume":"25","author":"Valent","year":"2001","journal-title":"Leuk Res"},{"key":"B3","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.iac.2018.04.003","article-title":"Hereditary alpha tryptasemia: genotyping and associated clinical features","volume":"38","author":"Lyons","year":"2018","journal-title":"Immunol Allergy Clin North Am"},{"key":"B4","first-page":"282","article-title":"Serum tryptase levels and markers of renal dysfunction in a population with chronic kidney disease","volume":"23","author":"Sirvent","year":"2010","journal-title":"J Nephrol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/j.jaci.2021.08.007","article-title":"Defining baseline variability of serum tryptase levels improves accuracy in identifying anaphylaxis","volume":"149","author":"Mateja","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1159\/000501079","article-title":"Why the 20%+2 tryptase formula is a diagnostic gold standard for severe systemic mast cell activation and mast cell activation syndrome","volume":"180","author":"Valent","year":"2019","journal-title":"Int Arch Allergy Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.aller.2014.05.002","article-title":"Clinical characteristics and risk profile of patients with elevated baseline serum tryptase","volume":"42","author":"Fellinger","year":"2014","journal-title":"Allergol Immunopathol (Madr)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1097\/ACI.0000000000000678","article-title":"Hymenoptera venom-induced anaphylaxis and hereditary alpha-tryptasemia","volume":"20","author":"O\u2019Connell","year":"2020","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1097\/ACI.0000000000000849","article-title":"Hereditary alpha-tryptasemia","volume":"22","author":"Bonadonna","year":"2022","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/gim.2017.136","article-title":"A common haplotype containing functional CACNA1H variants is frequently coinherited with increased TPSAB1 copy number","volume":"20","author":"Lyons","year":"2018","journal-title":"Genet Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1016\/j.jaip.2020.05.057","article-title":"Hereditary alpha-tryptasemia: UK prevalence and variability in disease expression","volume":"8","author":"Robey","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.3390\/ijms22052458","article-title":"Genetic regulation of tryptase production and clinical impact: hereditary alpha tryptasemia, mastocytosis and beyond","volume":"22","author":"Sprinzl","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1016\/j.jaip.2021.03.005","article-title":"The genetic basis and clinical impact of hereditary alpha-tryptasemia","volume":"9","author":"Luskin","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1084\/jem.20190701","article-title":"Impact of naturally forming human \u03b1\/\u03b2-tryptase heterotetramers in the pathogenesis of hereditary \u03b1-tryptasemia","volume":"216","author":"Le","year":"2019","journal-title":"J Exp Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"49","DOI":"10.12788\/cutis.0682","article-title":"Cutaneous manifestations in hereditary alpha tryptasemia","volume":"111","author":"Kranyak","year":"2023","journal-title":"Cutis"},{"key":"B16","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.anai.2021.01.016","article-title":"Hereditary alpha-tryptasemia in 101 patients with mast cell activation-related symptomatology including anaphylaxis","volume":"126","author":"Giannetti","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.jaci.2014.05.047","article-title":"Diminished reliability of tryptase as risk indicator of mastocytosis in older overweight subjects","volume":"135","author":"Vos","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1111\/j.1365-2222.2010.03582.x","article-title":"Serum total tryptase levels are increased in patients with active chronic urticaria","volume":"40","author":"Ferrer","year":"2010","journal-title":"Clin Exp Allergy"},{"key":"B19","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1182\/blood.2020006157","article-title":"Hereditary \u03b1 tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis","volume":"137","author":"Greiner","year":"2021","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1038\/ng.3696","article-title":"Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number","volume":"48","author":"Lyons","year":"2016","journal-title":"Nat Genet"},{"key":"B21","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.jaci.2021.06.017","article-title":"Hereditary alpha tryptasemia is not associated with specific clinical phenotypes","volume":"149","author":"Chollet","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.jaip.2022.11.042","article-title":"Mast cell activation syndromes: comparison between two scoring models to predict for mast cell clonality","volume":"11","author":"Rama","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B23","doi-asserted-by":"publisher","first-page":"152","DOI":"10.23822\/EurAnnACI.1764-1489.288","article-title":"Defining hereditary alpha-tryptasemia as a risk\/modifying factor for anaphylaxis: are we there yet?","volume":"55","author":"Couto","year":"2023","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"B24","first-page":"317","article-title":"The classification of allergic reactions underlying disease","volume-title":"Clinical Aspects of Immunology","author":"Gell","year":"1963"},{"key":"B25","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/S0140-6736(77)91953-5","article-title":"Incidence and severity of anaphylactoid reactions to colloid volume substitutes","volume":"1","author":"Ring","year":"1977","journal-title":"Lancet"},{"key":"B26","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1159\/000506199","article-title":"Elevated serum tryptase in non-anaphylaxis cases: a concise review","volume":"181","author":"Lee","year":"2020","journal-title":"Int Arch Allergy Appl Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1016\/j.jaip.2021.12.031","article-title":"Elevated basal serum tryptase: disease distribution and variability in a regional health system","volume":"10","author":"Waters","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/j.jaci.2022.04.025","article-title":"Differential mast cell mediators in systemic mastocytosis and hereditary \u03b1-tryptasemia","volume":"150","author":"Giannetti","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"3615","DOI":"10.1016\/j.jaip.2023.09.031","article-title":"Drug allergy in women","volume":"11","author":"Lee","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1111\/j.1398-9995.2008.01880.x","article-title":"Gender difference, sex hormones, and immediate type hypersensitivity reactions","volume":"63","author":"Chen","year":"2008","journal-title":"Allergy"},{"key":"B31","doi-asserted-by":"publisher","first-page":"S81","DOI":"10.1016\/j.anai.2021.08.252","article-title":"M098 A case of hereditary a-tryptasemia exacerbation following second dose of MRNA COVID-19 vaccine on omalizumab","volume":"127","author":"Li","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1089\/thy.2021.0361","article-title":"Sex differences in differentiated thyroid cancer","volume":"32","author":"Shobab","year":"2022","journal-title":"Thyroid\u00ae"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1001\/jama.2020.22196","article-title":"Autoimmune thyroid disease in women","volume":"325","author":"Mammen","year":"2021","journal-title":"JAMA"},{"key":"B34","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1159\/000508937","article-title":"Roles of thyroid hormones, mast cells, and inflammatory mediators in the initiation and progression of autoimmune thyroid diseases","volume":"181","author":"Zdor","year":"2020","journal-title":"Int Arch Allergy Immunol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"6203","DOI":"10.1038\/onc.2010.348","article-title":"Mast cells have a protumorigenic role in human thyroid cancer","volume":"29","author":"Melillo","year":"2010","journal-title":"Oncogene"},{"key":"B36","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1159\/000076480","article-title":"Association between chronic urticaria and thyroid autoimmunity: a prospective study involving 99 patients","volume":"208","author":"Verneuil","year":"2004","journal-title":"Dermatology"},{"key":"B37","first-page":"293","article-title":"Ige antithyroid antibodies in patients with Hashimoto\u2019s disease and chronic urticaria","volume":"25","author":"Concha","year":"2004","journal-title":"Allergy Asthma Proc"},{"key":"B38","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jdermsci.2008.04.002","article-title":"Sex hormones and urticaria","volume":"52","author":"Kasperska-Zajac","year":"2008","journal-title":"J Dermatol Sci"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e14794","DOI":"10.1371\/journal.pone.0014794","article-title":"Ige mediated autoallergy against thyroid peroxidase\u2013a novel pathomechanism of chronic spontaneous urticaria?","volume":"6","author":"Altrichter","year":"2011","journal-title":"PLoS One"},{"key":"B40","doi-asserted-by":"publisher","first-page":"53","DOI":"10.15386\/mpr-1598","article-title":"Comparison of immunoglobulin E anti-thyroid peroxidase antibodies in patients with Hashimoto thyroiditis and chronic spontaneous urticaria","volume":"94","author":"\u00c7ilda\u011f","year":"2021","journal-title":"Med Pharm Rep"},{"key":"B41","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1159\/000497235","article-title":"Serum baseline tryptase level as a marker for the severity of anaphylaxis","volume":"179","author":"Aniceto","year":"2019","journal-title":"Int Arch Allergy Immunol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1710-1492-10-19","article-title":"Non-steroidal anti-inflammatory drug hypersensitivity: association with elevated basal serum tryptase?","volume":"10","author":"Seitz","year":"2014","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e12132","DOI":"10.1002\/clt2.12132","article-title":"Mastocytosis presenting with mast cell-mediator release-associated symptoms elicited by cyclo oxygenase inhibitors: prevalence, clinical, and laboratory features","volume":"12","author":"Rama","year":"2022","journal-title":"Clin Transl Allergy"},{"key":"B44","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1093\/clinchem\/hvad206","article-title":"Hereditary alpha tryptasemia: validation of a single-well multiplex digital droplet PCR assay in a cohort of symptomatic patients","volume":"70","author":"Alheraky","year":"2024","journal-title":"Clin Chem"},{"key":"B45","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13601-019-0292-5","article-title":"Risk factors for severe systemic sting reactions in wasp (Vespula spp.) and honeybee (Apis mellifera) venom allergic patients","volume":"9","author":"Fehr","year":"2019","journal-title":"Clin Transl Allergy"}],"container-title":["Frontiers in Allergy"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2024.1461359\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T06:16:36Z","timestamp":1731392196000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2024.1461359\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,12]]},"references-count":45,"alternative-id":["10.3389\/falgy.2024.1461359"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2024.1461359","relation":{},"ISSN":["2673-6101"],"issn-type":[{"value":"2673-6101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,12]]},"article-number":"1461359"}}